Therapeutic proteins are highly specific in nature and carry out a complex set of functions which cannot be mimicked by simple chemical compound. Therapeutic proteins have higher immuntolerance and have advantages over small molecule drugs to alleviate diseases. Thetherapeutic proteins application is expected to continue growing at the highest CAGR
Erythropoietin(EPO, epoetin) protein hormoneErythropoietin is a peptide hormone. It is typically produced in the kidneys. Human recombinant erythropoietin is administered when a patient is not producing enough erythropoietin on his or her own. It can also be used to treat people with anemia. Erythropoietin responds to low oxygen levels in the body by regulating the production of more red blood cells. Amgen of USA has developed human recombinant erythropoietin and patented the product. The patent has expired and other generic versions (bio-similars) are in the market now.
Insulin is a peptide hormone and is central to regulating carbohydrate and fat metabolism in the body. Insulin causes cells in the liver, skeletal muscles and fat tissue to absorb glucose from blood. It helps in storing the glucose in the form of glycogen and helps the body get rid of excess glucose. When body stops production of adequate insulin, sugar levels in body go up (type I diabetes).
Diabetic patients have been treated with insulin derived from pancreas of abattoir animals (mainly pigs). Biotech based human insulin (R-Insulin) was approved for use in the 1980s. Hoechst was the first company to patent the drug. The patent has expired and other generic versions (biosimilar) are in the market now. Indus Gene will produce R-Insulin through the biotech route. More advanced analogs of insulin will be also taken up based on market needs.